share_log

Preston Klassen Sells 380,605 Shares of Metacrine, Inc. (NASDAQ:MTCR) Stock

Preston Klassen Sells 380,605 Shares of Metacrine, Inc. (NASDAQ:MTCR) Stock

普雷斯頓出售 380,605 股梅特克林公司股票
Defense World ·  2023/01/29 05:51

Metacrine, Inc. (NASDAQ:MTCR – Get Rating) CEO Preston Klassen sold 380,605 shares of the firm's stock in a transaction on Thursday, January 26th. The stock was sold at an average price of $0.41, for a total value of $156,048.05. Following the completion of the transaction, the chief executive officer now owns 541,905 shares of the company's stock, valued at approximately $222,181.05. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

梅塔克林公司（NASDAQ：MTCR-獲取評級）首席執行官普雷斯頓·克拉森於 1 月 26 日（星期四）在一次交易中出售了該公司股票的 380,605 股。該股票以 0.41 美元的平均價格出售，總價值 156,048.05 美元。交易完成後，首席執行官現擁有該公司股份的 541,905 股，價值約為 222,181.05 元。該銷售在向 SEC 提交的文件中披露，該文件可通過以下方式獲得 此超連結。

Metacrine Stock Performance

甲基林股票表現

NASDAQ MTCR opened at $0.48 on Friday. The stock has a 50-day simple moving average of $0.43 and a two-hundred day simple moving average of $0.45. The firm has a market capitalization of $20.44 million, a P/E ratio of -0.47 and a beta of -0.92. Metacrine, Inc. has a fifty-two week low of $0.30 and a fifty-two week high of $0.68. The company has a debt-to-equity ratio of 0.34, a quick ratio of 12.15 and a current ratio of 12.15.

納斯達克 MTCR 在周五開盤 0.48 美元。該股有一個 50 天的簡單移動平均線 0.43 美元和 200 天的簡單移動平均線 0.45 美元。該公司的市值為 20.44 萬美元，市盈率為 -0.47，貝塔值為 -0.92。梅塔克林擁有五十兩周低點 0.30 美元，五十二周高點為 0.68 美元。該公司的債務與權益比率為 0.34，快速比率為 12.15，流動比率為 12.15。

Get
取得
Metacrine
米塔克林
alerts:
警報：

Metacrine (NASDAQ:MTCR – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). On average, equities analysts forecast that Metacrine, Inc. will post -0.62 earnings per share for the current year.

甲基林（NASDAQ：MTCR-獲取評分）最近一次發布了其季度收益數據，週一，11 月 14 日。該公司報告了本季度每股盈利（0.13 美元），缺少分析師的共識估計為（0.11 美元）（0.02 美元）。平均而言，股票分析師預測，本年度 Metacrine Inc. 將公佈每股盈利 -0.62。

Hedge Funds Weigh In On Metacrine

對沖基金對甲基林的權衡

A number of institutional investors have recently modified their holdings of MTCR. State Street Corp raised its stake in shares of Metacrine by 482.8% during the 2nd quarter. State Street Corp now owns 72,186 shares of the company's stock valued at $36,000 after buying an additional 59,800 shares during the last quarter. Citadel Advisors LLC grew its position in shares of Metacrine by 112.5% during the 3rd quarter. Citadel Advisors LLC now owns 136,606 shares of the company's stock valued at $66,000 after acquiring an additional 72,306 shares during the period. Jane Street Group LLC acquired a new stake in shares of Metacrine during the 3rd quarter valued at about $84,000. Bank of New York Mellon Corp acquired a new stake in shares of Metacrine during the 1st quarter valued at about $126,000. Finally, Bank of America Corp DE grew its position in shares of Metacrine by 10.5% during the 1st quarter. Bank of America Corp DE now owns 263,340 shares of the company's stock valued at $161,000 after acquiring an additional 24,964 shares during the period. Hedge funds and other institutional investors own 34.28% of the company's stock.
一些機構投資者最近修改了他們對 MTCR 的持有量。州街公司在第二季度將其在梅特克林股份的股份增加了 482.8％。在上個季度額外購買 59,800 股股票後，州街公司現在擁有該公司股票的 72,186 股價值 36,000 美元。城堡顧問有限責任公司在第三季度增長了 112.5％ 在米特克林股份的地位。在此期間，城堡顧問有限責任公司現在擁有該公司股票的 136,606 股，價值為 66,000 美元。簡街集團有限責任公司在第三季度收購了 Metacrine 的新股份，價值約為 84,000 美元。紐約梅隆銀行在第一季度收購了價值約 126,000 美元的 Metacrine 股份的新股份。最後，美國銀行公司 DE 在第一季度增長了 10.5％ 在梅塔克林的股份地位。在此期間，美國銀行股份有限公司現在擁有該公司 263,340 股股份，價值為 161,000 美元。對沖基金和其他機構投資者擁有該公司股票的 34.28%。

Analysts Set New Price Targets

分析師設定新的價格目標

Separately, HC Wainwright restated a "neutral" rating on shares of Metacrine in a research note on Wednesday, November 16th.

此外，HC 溫賴特在 11 月 16 日（星期三）的一份研究報告中重申了對米克林股份的「中性」評級。

About Metacrine

關於梅塔克林

(Get Rating)

(取得評分)

Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.

Metacrine, Inc 是一家臨床階段生物製藥公司，致力於發現和開發針對胃腸疾病患者的療法。它正在開發 MET642，該試驗已完成治療潰瘍性結腸炎的 I 期臨床試驗。梅塔克林公司成立於 2014 年，總部位於加利福尼亞州聖地牙哥。

Featured Articles

特色文章

  • Get a free copy of the StockNews.com research report on Metacrine (MTCR)
  • MarketBeat Week in Review – 1/23- 1/27
  • Why Lucid Spiked Nearly 100% In One Day
  • Ride These Railroad Stocks for Growth and Income
  • ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
  • KLA Corporation: Strength In A Troubled Semi-Market
  • 獲取有關二甲基林（MTCR）的研究報告的免費副本
  • 市場節拍週的回顧 — 1/23-1/27
  • 為什麼清醒在一天內飆升近 100％
  • 乘坐這些鐵路股票以獲得增長和收入
  • ASML 今年看到籌碼需求上升，提高了銷售觀點
  • KLA 公司：陷入困境的半市場中的實力

Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.

接收梅塔克林日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Metacrine 及相關公司的最新新聞和分析師評級的簡要每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論